Cardiovascular Risk in Uremic Patients: Darkness after AURORA

REFERENCES

• Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Rosuvastatin and cardiovascular events in patients undergoing hemodiálisis. N Engl J Med. 2009;360:1395–1407.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. 2003;41:11–17.
   PubMed Web of Science ®Google Scholar
• Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356:147–152.
   PubMed Web of Science ®Google Scholar
• Liu Y, Coresh J, Eustace JA, Association between cholesterol level and mortality in dialysis patients. JAMA. 2004; 291:451–459.
   PubMed Web of Science ®Google Scholar
• Ritz E, Wanner C. Lipid changes and statins in chronic renal insufficiency. J Am Soc Nephrol. 2006;17 (Suppl. 3): S226–S230.
   Google Scholar
• Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron. 1982;31:103–110.
   PubMed Web of Science ®Google Scholar
• Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA. 2004;291:451–459.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Dyslipidaemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290:F262–F272.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation 2007;116: 85–97.
   PubMed Web of Science ®Google Scholar
• Yerkey MW, Kernis SJ, Franklin BA, Sandberg KR, McCullough PA. Renal dysfunction and acceleration of coronary disease. Heart. 2004;90:961–966.
   PubMedGoogle Scholar
• Robles NR, Romero J, Gomez Casero L, Escola JM, Ramos Salado JL, Sánchez Casado E. Hyperhomocysteinemia in chronic kidney patients with mild renal failure. Eur J Intern Med. 2005;16:334–338.
   PubMedGoogle Scholar
• Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879–885.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G, Cholesterol and Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112: 2627–2633.
   PubMed Web of Science ®Google Scholar
• Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, PREPARE Study Group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007;22:2909–2916.
   PubMed Web of Science ®Google Scholar
• Schlieper G, Krüger T, Djuric Z, Damjanovic T, Markovic N, Schurgers JL, Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int. 2008;74: 1582–1587.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252.
   PubMed Web of Science ®Google Scholar
• Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998;339:1972–1978.
   PubMed Web of Science ®Google Scholar
• Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: The St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005;46:166–172.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Agrawal V, Danielewicz E, Abela GS. Accelerated atherosclerotic calcification and Mönckeberg's sclerosis: A continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3: 1585–1598.
   PubMed Web of Science ®Google Scholar
• Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–658.
   PubMed Web of Science ®Google Scholar
• Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int. 2002;62:620–626.
   PubMed Web of Science ®Google Scholar
• David S, Tetta C, Canino F, Gervasio R, Cambi V. Production of platelet activating factor by human neutrophils after backfiltration of endotoxin contaminated dialysate. ASAIO J. 1993;39:M773–M777.
   Google Scholar
• Parker TF III, Wingard RL, Husni L, Ikizler TA, Parker RA, Hakim RM. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int. 1996;49:551–556.
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212–1218.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstron J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000;15:953–960.
   PubMed Web of Science ®Google Scholar
• Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003;41:1364–1372.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009;373: 1175–1182.
   PubMed Web of Science ®Google Scholar
• Baigent C, Laundry M. Study of Heart and Renal Protection (SHARP). Kidney Int. 2003;63 (Suppl. 84):S207–S210.
   Google Scholar
• K/DOQI Clinical Practice Guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41 (Suppl. 3):S1–S91.
   PubMedGoogle Scholar
• Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353: 238–248.
   PubMed Web of Science ®Google Scholar
• Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White H; on behalf of the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105: 1446–1452.
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. Circulation. 2002;106:1024–1028.
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Craig JC. Sunset for statins after AURORA? N Engl J Med. 2009;360:1455–1457.
   PubMedGoogle Scholar